D. Medical Industries Ltd. (DMED) Signs Deal with Edgepark Medical Supplies and Independence Medical to Distribute Infusion Sets

QualityStocks would like to highlight D. Medical (NASDAQ: DMED), an Israeli medical device company engaged through its subsidiaries in the research, development, manufacture, and sale of innovative products for diabetes treatment and drug delivery.

In the company’s news yesterday,

D. Medical announced that it has worked out a deal to distribute its Spring(TM) Universal Infusion Sets in the United States. D. Medical’s subsidiary, Spring Health Solutions Inc., has agreed to give RGH Enterprises, Inc., the parent company of Edgepark Medical Supplies and Independence Medical, a non-exclusive distribution deal for the Infusion Sets to facilitate the product’s immediate commercial rollout in the world’s single largest insulin pump and disposables market.

The Spring Universal Infusion Set features a hidden, auto-retractable needle, 360 connector and the smallest, one-click, all-in-one inserter. The core of the Spring Universal Infusion Set is the proprietary Detach-Detect mechanism. In the case the base of the infusion set detaches from the user’s body, a blocking mechanism is triggered which creates an occlusion and sets off an alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind – especially for athletes and the parents of pediatric patients. The Spring Universal Infusion Set works with most insulin pumps on the market today.

“The annual market for infusion sets is estimated to total $730 million in the U.S. alone – yet there has been little or no design innovation in this category in recent past. We believe that the clear advantages of our Spring Universal Infusion sets, combined with the fact that they will be available through a market leaders like Edgepark Medical Supplies and Independence Medical, will lead to maximized penetration into what was, heretofore a largely commoditized product market,” said Efri Argaman, D. Medical’s Chief Executive Officer, in a press release today.

The United States has approximately 26 million diabetes patients with 1.4 million suffering from Type 1 diabetes and about 350,000 currently rely on insulin pump therapy for treatment. A recent U.S. Centers for Disease Control and Prevention report estimated that 1 in 3 Americans will have diabetes by 2050 if current trends continue.

D. Medical is focused on research and development that will lead to the next generation of insulin pumps. To learn more about D. Medical’s research, please visit www.dmedicalindustries.com

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.